

CONTENTS VOL. 15, No. 1, 1996

HEAD AND NECK TUMORS

Overview

| | |
|---|---------|
| Head and neck tumors W.K. Hong | 1-2 |
| Molecular staging of head and neck squamous carcinoma J.A. Brennan and D. Sidransky | 3-10 |
| Biological staging of head and neck cancer and its role in developing effective treatment strategies W.M. Lydiatt and S.P. Schantz | 11-25 |
| Cell, tissue and organ culture as <i>in vitro</i> models to study the biology of squamous cell carcinomas of the head and neck P.G. Sacks | 27-51 |
| Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis V.A. Papadimitrakopoulou, D.M. Shin and W.K. Hong | 53-76 |
| Invasion and metastasis D. Boyd | 77-89 |
| A possible role for human papillomaviruses in head and neck cancer B.M. Steinberg and T.P. DiLorenzo | 91-112 |
| Clinical studies in head and neck cancer chemoprevention P.M. Gonzalez and S.E. Benner | 113-118 |
| Programmed cell death and radioresistance R.E. Meyn, L.C. Stephens and L. Milas | 119-131 |
| The clinical application of DNA content and kinetic parameters in the treatment of patients with squamous cell carcinomas of the head and neck J.F. Ensley | 133-141 |
| Instructions for authors | 143-144 |

CONTENTS VOL. 15, No. 2, June 1996

TUMOR ANGIOGENESIS

Overview

| | |
|--|---------|
| Commentaries on tumor angiogenesis: An introduction R.S. Kerbel | 145-147 |
| What, if anything, is an angiogenic factor? W. Risau | 149-151 |
| Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants G. Neufeld, T. Cohen, H. Gitay-Goren, Z. Poltorak, S. Tessler, R. Sharon, S. Gengrinovitch and B.-Z. Levi | 153-158 |
| Biological properties of VEGF/VPF receptors B.I. Terman and M. Dougher-Vermazen | 159-163 |
| Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis K.P. Claffey and G.S. Robinson | 165-176 |
| Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor I. Vlodavsky, H.-Q. Miao, B. Medalion, P. Danagher and D. Ron | 177-186 |
| Cell adhesion molecules in angiogenesis P.C. Brooks | 187-194 |
| Leukocyte-endothelial adhesion and angiogenesis in tumors R.K. Jain, G.C. Koenig, M. Dellian, D. Fukumura, L.L. Munn and R.J. Melder | 195-204 |
| Tumor angiogenesis: A physiological process or genetically determined? P.A. D'Amore and D.T. Shima | 205-212 |
| The role of angiogenic growth factors in breast cancer progression F.G. Kern and M.E. Lippman | 213-219 |
| Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target J.P. Crew, T.S. O'Brien and A.L. Harris | 221-230 |
| Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls J. Rak and R.S. Kerbel | 231-236 |
| Gene therapy of malignant glioma via inhibition of tumor angiogenesis K.H. Plate | 237-240 |
| Antiangiogenesis restricted tumor dormancy L. Holmgren | 241-245 |
| A systems approach to cancer therapy B.A. Teicher | 247-272 |
| Liver endothelial cells: Participation in host response to lymphoma metastasis V. Umansky, M. Rocha and V. Schirmacher | 273-279 |
| Instructions for authors | 281-282 |

CONTENTS VOL. 15, No. 3, September 1996

GENE THERAPY OF CANCER

| | |
|---|---------|
| Gene therapy for cancer – in the dock, blown off course or full speed ahead? R.C. Vile | 283–286 |
| Antisense approaches to the gene therapy of cancer – ‘Recnac’ I. Gibson | 287–299 |
| Direct cell killing by suicide genes L.-A. Martin and N.R. Lemoine | 301–316 |
| Immunotherapy I: Cyclosine gene transfer strategies M.P. Colombo and G. Forni | 317–328 |
| Immunotherapy II: Antigens, receptors and costimulation P.F. Searle and L.S. Young | 329–349 |
| Immunotherapy III: Combinatorial molecular immunotherapy – a synthesis and suggestions R.G. Vile and H. Chong | 351–364 |
| Chemoprotection of normal tissues by transfer of drug resistance gene J.A. Rafferty, I. Hickson, N. Chinnasamy, L.S. Lashford, G.P. Margison, T.M. Dexter and L.J. Fairbairn | 365–383 |
| Vectors for cancer gene therapy J. Zhang and S.J. Russell | 385–401 |
| <i>Overview</i> | |
| Gene therapy for cancer, the course ahead R.G. Vile | 403–410 |
| Instructions for authors | 411–412 |

INTERMEDIATE FILAMENTS

| | |
|--|---------|
| Intermediate filaments M.J.C. Hendrix | 413-416 |
| Intermediate filaments as dynamic structures M.W. Klymkowsky | 417-428 |
| Implications of intermediate filament protein phosphorylation Nam-On Ku, Jian Liao, Chih-Fong Chou and M. Bishr Omary | 429-444 |
| Oncogenic regulation and function of keratins 8 and 18 R.G. Oshima, H. Baribault and C. Caulin | 445-471 |
| Intermediate filament expression in prostate cancer R.B. Nagle | 473-482 |
| Intermediate filaments in the nervous system: implications in cancer Chung-Liang Ho, Ronald K.H. Liem | 483-497 |
| Multiple drug resistance and intermediate filaments A.E. Cress, W.S. Dalton | 499-506 |
| Role of intermediate filaments in migration, invasion and metastasis M.J.C. Hendrix, E.A. Seftor, Yi-Wen Chu, K.T. Trevor and R.E.B. Seftor | 507-525 |
| Volume contents | 527-530 |
| Instructions for authors | 531-532 |

